XASE
STXS
Market cap108mUSD
Oct 08, Last price
1.11USD
1D
-1.77%
1Q
-34.71%
Jan 2017
70.80%
IPO
-98.52%
Name
Stereotaxis Inc
Chart & performance
P/E
—
P/S
3.36
EPS
—
Div yield, %
—
Shrs. gr., 5y
4.57%
Rev. gr., 5y
3.99%
Revenues
32m
+20.28%
Net income
-22m
L-9.99%
CFO
-14m
L+61.06%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Stereotaxis, Inc. designs, manufactures and markets robotic magnetic navigation systems for use in a hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. Its products include the Genesis RMN System, the Odyssey Solution, and related devices. The firm also offers the Stereotaxis Imaging Model S x-ray System. The company was founded in June 1990 and is headquartered in St. Louis, MO.
Key people
Kimberly Peery
Chief Financial Officer · since 2019
David Benfer
Lead Independent Director · since 2015
Nathan Fischel
Director · since 2017
David Fischel
Chairman of the Board, Chief Executive Officer · since 2017
Director · since 2024
Independent Director · since 2021
Independent Director · since 2018
Independent Director · since 2016
Legal address
C/O COGENCY GLOBAL INC.
850 NEW BURTON ROAD
SUITE 201
DOVER, DE 19904
US
850 NEW BURTON ROAD
SUITE 201
DOVER, DE 19904
US
Headquarters
4320 Forest Park Avenue
Suite 100
Saint Louis, MO 63108
US
Suite 100
Saint Louis, MO 63108
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||